Indications
Vemlidy is indicated for the treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.1).
Composition
- Active substance
- tenofovir alafenamide fumarate
- International name (INN)
- tenofovir alafenamide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vemlidy
- Active substance
- tenofovir alafenamide fumarate
- ATC code
- J05AF13
- Therapeutic area
- Hepatitis B
- Marketing authorisation holder
- Gilead Sciences Ireland UC